Biocon Biologics To Acquire Viatris Inc's Biosimilars Business

Biocon Biologics to acquire Viatris Inc's biosimilars business

The Hindu businessline

Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership

Biocon Biologics

Biocon Biologics to Acquire Viatris Global Biosimilars Assets for upto USD 3.335 bn in stock & cash

Biocon Biologics

Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says

CNBC International Live

Biocon Biologics' Management On Acquiring Biosimilars Business Of Viatris

Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business

Biocon To Buy Viatris' Assets | Kiran Shaw On The Deal Rationale

Biocon Sells 5.4% Stake In Syngene To Fund Viatris Biologics Biz Acquisition | Halftime Report

Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO

CNBC International Live

Biocon Biologics completes integration of Viatris' biosimilar business in 120 countries

sharemarket9999

Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map

Biocon Goes Shopping

Biocon's Siddharth Mittal Speaks On Selling Stake In Syngene & Viatris Biologics Biz Acquisition

Biocon Biologics: Revolutionizing Healthcare with Biosimilars

Biocon Biologics

NDTV Profit Exclusive | Biocon Biologics' Kiran Mazumdar Shaw On Viatris' Acquisition

Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months

Biocon Biologics: Enabling Equitable Access to Affordable Healthcare

Biocon Biologics

Biocon Biologics acquires Viatris' biosimilars business in $3.3 bn deal

The Power of One: What happens when ideas come together to become one?

Biocon Biologics

Biocon Biologics ISPE FOYA Award

ISPE